Ronald W. Barrett
Director/Board Member at JANUX THERAPEUTICS, INC.
Net worth: - $ as of 29/04/2024
Ronald W. Barrett active positions
Companies | Position | Start | End |
---|---|---|---|
JANUX THERAPEUTICS, INC. | Director/Board Member | 06/09/2021 | - |
Medikine, Inc.
Medikine, Inc. Pharmaceuticals: MajorHealth Technology Medikine, Inc. is a privately held biopharmaceutical company located in an undisclosed location. The American company's mission is to transform the discovery of oncology, autoimmune disorder, and infectious disease therapeutics by employing a versatile drug discovery platform that generates modular "peptikines." These peptikines are peptide mimetics of cytokines that are smaller in molecular size than, and structurally unrelated to, the natural cytokines they emulate. Medikine's lead candidate, mdk-703, is currently in a phase 1 clinical trial in healthy volunteers. Ronald W. Barrett has been the CEO of the company since 2016. | Chief Executive Officer | 31/05/2017 | - |
Chairman | 30/11/2016 | - | |
Quadriga BioSciences, Inc.
Quadriga BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Quadriga BioSciences, Inc. is a privately held pharmaceutical company based in an undisclosed location. The American company is focused on developing proprietary targeted cancer therapies by exploiting the biology of aggressive forms of cancer cells that over-express certain unique amino acid transporters on their cell surfaces. The company's mission is to develop safer and more effective treatments for patients with cancer. The company was founded by Bernd Jandeleit, Kerry J. Koller, and Wolf-Nicolas Fischer. Gordon Ringold has been the CEO of the company since 2015. | Director/Board Member | - | - |
Career history of Ronald W. Barrett
Former positions of Ronald W. Barrett
Companies | Position | Start | End |
---|---|---|---|
CONCERT PHARMACEUTICALS, INC. | Director/Board Member | 30/11/2007 | 08/06/2022 |
Independent Dir/Board Member | 15/01/2014 | 08/06/2022 | |
XENOPORT, INC. | Director/Board Member | 16/12/1999 | 28/09/2015 |
Chief Executive Officer | 31/12/2000 | 28/09/2015 | |
Chief Tech/Sci/R&D Officer | 16/12/1999 | 31/12/2000 | |
Founder | 16/12/1999 | 28/09/2015 | |
Affymax Research Institute
Affymax Research Institute Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, Affymax Research Institute is a company that researches and develops pharmaceutical products. The company is based in Palo Alto, CA. Affymax Research Institute was acquired by Affymax, Inc. from GSK Plc on July 30, 2001. | Chief Tech/Sci/R&D Officer | 31/12/1988 | 31/12/1998 |
ABBOTT LABORATORIES | Corporate Officer/Principal | 31/12/1988 | 31/12/1988 |
Quadriga BioSciences, Inc.
Quadriga BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Quadriga BioSciences, Inc. is a privately held pharmaceutical company based in an undisclosed location. The American company is focused on developing proprietary targeted cancer therapies by exploiting the biology of aggressive forms of cancer cells that over-express certain unique amino acid transporters on their cell surfaces. The company's mission is to develop safer and more effective treatments for patients with cancer. The company was founded by Bernd Jandeleit, Kerry J. Koller, and Wolf-Nicolas Fischer. Gordon Ringold has been the CEO of the company since 2015. | Director/Board Member | - | - |
Training of Ronald W. Barrett
Bucknell University | Undergraduate Degree |
Rutgers State University of New Jersey | Doctorate Degree |
Statistics
International
United States | 10 |
Operational
Director/Board Member | 5 |
Chief Executive Officer | 2 |
Chief Tech/Sci/R&D Officer | 2 |
Sectoral
Health Technology | 7 |
Consumer Services | 3 |
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
ABBOTT LABORATORIES | Health Technology |
JANUX THERAPEUTICS, INC. | Health Technology |
Private companies | 5 |
---|---|
Concert Pharmaceuticals, Inc.
Concert Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA. | Health Technology |
Affymax Research Institute
Affymax Research Institute Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, Affymax Research Institute is a company that researches and develops pharmaceutical products. The company is based in Palo Alto, CA. Affymax Research Institute was acquired by Affymax, Inc. from GSK Plc on July 30, 2001. | Commercial Services |
XenoPort, Inc.
XenoPort, Inc. Pharmaceuticals: MajorHealth Technology XenoPort, Inc. operated as a biopharmaceutical company. Its products included horizant and regnite. The company was founded by Ronald W. Barrett, William J. Dower and Mark A. Gallop on December 17, 1999 and was headquartered in Atlanta, GA. | Health Technology |
Quadriga BioSciences, Inc.
Quadriga BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Quadriga BioSciences, Inc. is a privately held pharmaceutical company based in an undisclosed location. The American company is focused on developing proprietary targeted cancer therapies by exploiting the biology of aggressive forms of cancer cells that over-express certain unique amino acid transporters on their cell surfaces. The company's mission is to develop safer and more effective treatments for patients with cancer. The company was founded by Bernd Jandeleit, Kerry J. Koller, and Wolf-Nicolas Fischer. Gordon Ringold has been the CEO of the company since 2015. | Health Technology |
Medikine, Inc.
Medikine, Inc. Pharmaceuticals: MajorHealth Technology Medikine, Inc. is a privately held biopharmaceutical company located in an undisclosed location. The American company's mission is to transform the discovery of oncology, autoimmune disorder, and infectious disease therapeutics by employing a versatile drug discovery platform that generates modular "peptikines." These peptikines are peptide mimetics of cytokines that are smaller in molecular size than, and structurally unrelated to, the natural cytokines they emulate. Medikine's lead candidate, mdk-703, is currently in a phase 1 clinical trial in healthy volunteers. Ronald W. Barrett has been the CEO of the company since 2016. | Health Technology |
- Stock Market
- Insiders
- Ronald W. Barrett
- Experience